156 related articles for article (PubMed ID: 19833861)
1. Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects.
Lauring B; Dishy V; Luo WL; Laterza O; Patterson J; Cote J; Chao A; Larson P; Gutierrez M; Wagner JA; Lai E
J Clin Pharmacol; 2009 Dec; 49(12):1426-35. PubMed ID: 19833861
[TBL] [Abstract][Full Text] [Related]
2. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.
Dishy V; Liu F; Ebel DL; Atiee GJ; Royalty J; Reilley S; Paolini JF; Wagner JA; Lai E
J Clin Pharmacol; 2009 Apr; 49(4):416-22. PubMed ID: 19246721
[TBL] [Abstract][Full Text] [Related]
3. Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects.
Lai E; Schwartz JI; Dallob A; Jumes P; Liu F; Kraft WK; Royalty J; Chodakewitz JA; McCrary Sisk C; Radziszewski W; Wagner JA
Platelets; 2010; 21(3):191-8. PubMed ID: 20163197
[TBL] [Abstract][Full Text] [Related]
4. The effects of laropiprant, a selective prostaglandin D₂ receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin.
Dallob A; Luo WL; Luk JM; Ratcliffe L; Johnson-Levonas AO; Schwartz JI; Dishy V; Kraft WK; De Hoon JN; Van Hecken A; De Lepeleire I; Radziszewski W; Wagner JA; Lai E
Platelets; 2011; 22(7):495-503. PubMed ID: 21526889
[TBL] [Abstract][Full Text] [Related]
5. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
[TBL] [Abstract][Full Text] [Related]
6. Effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the steady-state pharmacokinetics of digoxin in healthy adult subjects.
Liu F; Vessey L; Wenning L; Connolly S; Buckland M; Johnson-Levonas AO; Denker A; Wagner JA; Lai E
J Clin Pharmacol; 2010 Jul; 50(7):823-8. PubMed ID: 20197486
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist.
Lai E; Wenning LA; Crumley TM; De Lepeleire I; Liu F; de Hoon JN; Van Hecken A; Depré M; Hilliard D; Greenberg H; O'Neill G; Metters K; Gottesdiener KG; Wagner JA
Clin Pharmacol Ther; 2008 Jun; 83(6):840-7. PubMed ID: 17882161
[TBL] [Abstract][Full Text] [Related]
8. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF
Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443
[TBL] [Abstract][Full Text] [Related]
9. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
Paolini JF; Mitchel YB; Reyes R; Kher U; Lai E; Watson DJ; Norquist JM; Meehan AG; Bays HE; Davidson M; Ballantyne CM
Am J Cardiol; 2008 Mar; 101(5):625-30. PubMed ID: 18308010
[TBL] [Abstract][Full Text] [Related]
10. A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.
Yiu KH; Cheung BM; Tse HF
Expert Opin Investig Drugs; 2010 Mar; 19(3):437-49. PubMed ID: 20141348
[TBL] [Abstract][Full Text] [Related]
11. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1.
Lai E; De Lepeleire I; Crumley TM; Liu F; Wenning LA; Michiels N; Vets E; O'Neill G; Wagner JA; Gottesdiener K
Clin Pharmacol Ther; 2007 Jun; 81(6):849-57. PubMed ID: 17392721
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
Shah S; Ceska R; Gil-Extremera B; Paolini JF; Giezek H; Vandormael K; Mao A; McCrary Sisk C; Maccubbin D
Int J Clin Pract; 2010 May; 64(6):727-38. PubMed ID: 20518948
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of laropiprant and glucuronide metabolite in patients with severe renal insufficiency.
Stroh M; Wenning L; Luo WL; Desai R; Bi S; Keshavarz S; Lazarus N; Lunde NM; Smith WB; Schwartz M; Stone J; Wagner J; Lai E; Dishy V
Am J Ther; 2009; 16(5):379-84. PubMed ID: 19433974
[TBL] [Abstract][Full Text] [Related]
14. Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes.
Bostom AG; Maclean AA; Maccubbin D; Tipping D; Giezek H; Hanlon WA
J Clin Lipidol; 2011; 5(4):281-7. PubMed ID: 21784373
[TBL] [Abstract][Full Text] [Related]
15. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.
Paolini JF; Bays HE; Ballantyne CM; Davidson M; Pasternak R; Maccubbin D; Norquist JM; Lai E; Waters MG; Kuznetsova O; Sisk CM; Mitchel YB
Cardiol Clin; 2008 Nov; 26(4):547-60. PubMed ID: 19031552
[TBL] [Abstract][Full Text] [Related]
16. Safety of extended-release niacin/laropiprant in patients with dyslipidemia.
McKenney J; Bays H; Koren M; Ballantyne CM; Paolini JF; Mitchel Y; Betteridge A; Kuznetsova O; Sapre A; Sisk CM; Maccubbin D
J Clin Lipidol; 2010; 4(2):105-112.e1. PubMed ID: 21122637
[TBL] [Abstract][Full Text] [Related]
17. Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.
Schwartz JI; Liu F; Wang YH; Pramanik B; Johnson-Levonas AO; Gutierrez MJ; Lai E; Wagner JA
Am J Ther; 2009; 16(6):487-95. PubMed ID: 19940609
[TBL] [Abstract][Full Text] [Related]
18. Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone.
Schwartz JI; Stroh M; Gao B; Liu F; Rosko K; Zajic S; Meehan AJ; Ruckle J; Lai E; Wagner JA
Cardiovasc Ther; 2009; 27(4):239-45. PubMed ID: 19903187
[TBL] [Abstract][Full Text] [Related]
19. Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients.
Bays HE; Maccubbin D; Meehan AG; Kuznetsova O; Mitchel YB; Paolini JF
Clin Ther; 2009 Jan; 31(1):115-22. PubMed ID: 19243712
[TBL] [Abstract][Full Text] [Related]
20. Effects of Extended-Release Niacin and Extended-Release Niacin/Laropiprant on the Pharmacokinetics of Simvastatin in Healthy Subjects.
Lauring B; Dishy V; De Kam PJ; Crumley T; Wenning L; Liu F; Sisk C; Wagner J; Lai E
Am J Ther; 2015; 22(5):367-76. PubMed ID: 24832384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
